Skip to main content

Advertisement

SpringerLink
Log in

The role of the clinical pharmacist in the prevention of potential drug interactions in geriatric heart failure patients

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background The treatment of heart failure patients is very complex and includes lifestyle modification as well as different pharmacological therapies. Polypharmacy is very common in such patients and they are at increased risk of potential drug–drug interactions and associated effects such as poor adherence, compliance and adverse events. Objective The aim of the present study is to investigate retrospectively the prescribed pharmacotherapy of the hospital discharged heart failure patients for possible drug interactions. Settings Clinic for Cardiology of the “Saint Marina” University Hospital in Varna, Bulgaria. Method Lexicomp® Drug interaction software was used for screening potential drug–drug interactions. Logistic regression was applied to determine the odds ratio for the association between the age and number of drugs taken and the number of potential drug–drug interactions. Main outcome measure Incidence and type of pDDIs in geriatric heart failure patients. Results A retrospective study was conducted by reviewing the medical records of 248 selected heart failure patients for the prescribed medicines for a 1-year period (January 2015–December 2015). The total number of potential drug–drug interactions was 1532, or approximately 6.28 (± 4.72 SD) per one person. The range of prescribed drugs was between three and fourteen, 92% of them have been taking more than five medicines, an average of 7.12 (± 2.07 SD) per patient. The average age was 72.35 (± 10.16 SD). The results have shown stronger association between the number of drugs taken (more than 7) and the occurrence of potential drug–drug interactions (more than 10)—37.84 (95% CI 9.012–158.896, P ≤ 0.001). No statistically significant differences were found between age and occurrence of potential drug–drug interactions (more than 10)—1.008 (95% CI 0.441–2.308, P = 0.848). Conclusion The incidence of drug-drug interactions in heart failure patients is high. The clinical pharmacist, as a part of the multidisciplinary team, could reduce medication-related problems, such as drug interactions, and to optimize drug therapy by checking the treatment prescribed at the discharge of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012;2:365–71.

    Article  Google Scholar 

  2. Shah A, Gandhi D, Srivastava S, Shah KJ, Mansukhani R. Heart failure: a class review of pharmacotherapy. Pharm Ther. 2017;42:464–72.

    Google Scholar 

  3. von Lueder TG, Atar D. Comorbidities and polypharmacy. Heart Fail Clin. 2014;10:367–72.

    Article  Google Scholar 

  4. Squizzato A, Bellesini M, Takeda A, Middeldorp S, Donadini MP. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;12:CD005158.

    PubMed  Google Scholar 

  5. Cooper LB, Hernandez AF. Assessing the quality and comparative effectiveness of team-based care for heart failure: who, what, where, when, and how. Heart Fail Clin. 2015;11:499–506.

    Article  Google Scholar 

  6. Kalisch LM, Roughead EE, Gilbert AL. Improving heart failure outcomes with pharmacist-physician collaboration: how close are we? Future Cardiol. 2010;6:255–68.

    Article  Google Scholar 

  7. Anderson SL, Marrs JC. A review of the role of the pharmacist in heart failure transition of care. Adv Ther. 2018;35:311–23.

    Article  Google Scholar 

  8. Lexicomp® interaction analyser (Lexicomp® Inc., Ohio, USA). http://www.uptodate.com. Accessed 21 Dec 2018.

  9. Faulx MD, Francis GS. Adverse drug reactions in patients with cardiovascular disease. Curr Probl Cardiol. 2008;33:703–68.

    Article  Google Scholar 

  10. Straubhaar B, Krähenbühl S, Schlienger RG. The prevalence of potential drug–drug interactions in patients with heart failure at hospital discharge. Drug Saf. 2006;29:79–90.

    Article  Google Scholar 

  11. Roblek T, Trobec K, Mrhar A, Lainscak M. Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease. Arch Med Sci. 2014;10:920–32.

    Article  CAS  Google Scholar 

  12. Sharma S, Chhetri HP, Alam K. A study of potential drug-drug interactions among hospitalized cardiac patients in a teaching hospital in Western Nepal. Indian J Pharmacol. 2014;46:152–6.

    Article  Google Scholar 

  13. Mateti U, Rajakannan T, Nekkanti H, Rajesh V, Mallaysamy S, Ramachandran P. Drug–drug interactions in hospitalized cardiac patients. J Young Pharm. 2011;3:329–33.

    Article  Google Scholar 

  14. Ismail M, Iqbal Z, Khattak MB, Khan MI, Arsalan H, Javaid A, et al. Potential drug–drug interactions in internal medicine wards in hospital setting in Pakistan. Int J Clin Pharm. 2013;35:455–62.

    Article  CAS  Google Scholar 

  15. Murtaza G, Khan MY, Azhar S, Khan SA, Khan TM. Assessment of potential drug–drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharm J. 2015;24:220–5.

    Article  Google Scholar 

  16. Bergkvist A, Midlov P, Hoglund P, Larsson L, Bondesson A, Eriksson T. Improved quality in the hospital discharge summary reduces medication errors—LIMM: landskrona Integrated Medicines Management. Eur J Clin Pharmacol. 2009;65:1037–46.

    Article  Google Scholar 

  17. Graabaek T, Kjeldsen LJ. Medication reviews by clinical pharmacists at hospitals lead to improved patient outcomes: a systematic review. Basic Clin Pharmacol Toxicol. 2013;112:359–73.

    Article  CAS  Google Scholar 

  18. Ravn-Nielsen LV, Duckert ML, Lund ML, Henriksen JP, Nielsen ML, Eriksen CS, et al. Effect of an In-hospital multifaceted clinical pharmacist intervention on the risk of readmission: a randomized clinical trial. JAMA Intern Med. 2018;178:375–82.

    Article  Google Scholar 

  19. Hohl CM, Partovi N, Ghement I, Wickham ME, McGrail K, Reddekopp LN, et al. Impact of early in-hospital medication review by clinical pharmacists on health services utilization. PLoS ONE. 2017;12:e0170495.

    Article  Google Scholar 

  20. Roblek T, Deticek A, Leskovar B, Suskovic S, Horvat M, Belic A, et al. Clinical-pharmacist intervention reduces clinically relevant drug–drug interactions in patients with heart failure: a randomized, double-blind, controlled trial. Int J Cardiol. 2016;203:647–52.

    Article  Google Scholar 

  21. Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J, Faus Felipe V. Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm. 2014;36:1251–9.

    Article  Google Scholar 

  22. Gatwood J, Gatwood K, Gabre E, Alexander M. Impact of clinical pharmacists in outpatient oncology practices: a review. Am J Health Syst Pharm. 2017;74:1549–57.

    Article  Google Scholar 

  23. Dolovich L, Austin Z, Waite N, Chang F, Farrell B, Grindrod K, et al. Pharmacy in the 21st century: enhancing the impact of the profession of pharmacy on people’s lives in the context of health care trends, evidence and policies. Can Pharm J. 2018;152:45–53.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the colleagues from the Cardiology Clinic at St. Marina University Hospital in Varna, Bulgaria for the provided data.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Technologies, Faculty of Pharmacy, Medical University “Prof. Dr. Paraskev Stoyanov”, Varna, Bulgaria

    Kaloyan D. Georgiev

  2. Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University “Prof. Dr. Paraskev Stoyanov”, Varna, Bulgaria

    Nadezhda Hvarchanova & Marieta Georgieva

  3. Department of Internal Medicine, UMHAT “St. Marina”, Faculty of Medicine, Medical University “Prof. Dr. Paraskev Stoyanov”, Varna, Bulgaria

    Branimir Kanazirev

Authors
  1. Kaloyan D. Georgiev
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nadezhda Hvarchanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marieta Georgieva
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Branimir Kanazirev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kaloyan D. Georgiev.

Ethics declarations

Conflicts of interest

The authors have no conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Georgiev, K.D., Hvarchanova, N., Georgieva, M. et al. The role of the clinical pharmacist in the prevention of potential drug interactions in geriatric heart failure patients. Int J Clin Pharm 41, 1555–1561 (2019). https://doi.org/10.1007/s11096-019-00918-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-019-00918-z

Keywords

Search

Navigation